Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
Zentalis Pharmaceuticals reported its full-year 2025 financial results highlighting significant milestones in the development of azenosertib, a potentially first-in-class WEE1 inhibitor targeted at Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Key operational updates include completion of dose confirmation enrollment in the DENALI Pa…